Dr. Saxena on the Future of Next-Generation ALK Inhibitors in NSCLC

Supplements And Featured PublicationsTargeted Advances in ALK+ NSCLC
Volume 1
Issue 1

In Partnership With:

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the future of next-generation ALK inhibitors in non—small cell lung cancer (NSCLC).

Alectinib (Alecensa) and brigatinib (Alunbrig) have not been compared in a head-to-head clinical trial, says Saxena.

It appears that brigatinib has a higher sensitivity to certain resistance mutations versus alectinib, adds Saxena. However, it is unknown whether that translates to a longer progression-free survival.

The question of what to give patients who progress on a second-line ALK inhibitor like lorlatinib (Lorbrena) remains an area of active investigation, explains Saxena. Likely, chemotherapy would be the optimal option; however, potential novel agents and combination strategies are under evaluation.

Related Videos
Arutha Kulasinghe, PhD
Andrea Billè, MD
Experts on lung cancer
Experts on lung cancer
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Joachim G. J. V. Aerts, MD, PhD
Alessandro Di Federico, MD
Expert on SCLC
Dazhi Liu, PharmD, MS, BCOP
Stephen V. Liu, MD
Related Content